BeiGene (NASDAQ:BGNE) Sets New 12-Month Low at $131.50

BeiGene, Ltd. (NASDAQ:BGNE)’s share price hit a new 52-week low during trading on Wednesday . The stock traded as low as $131.50 and last traded at $131.83, with a volume of 48835 shares trading hands. The stock had previously closed at $134.05.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on BGNE shares. Bank of America lowered their price target on BeiGene from $179.30 to $164.30 and set a “neutral” rating for the company in a report on Monday, April 8th. Sanford C. Bernstein dropped their price target on shares of BeiGene from $196.00 to $161.00 and set a “market perform” rating for the company in a research report on Wednesday, March 27th. JPMorgan Chase & Co. upped their price objective on shares of BeiGene from $184.00 to $186.00 and gave the stock an “overweight” rating in a report on Tuesday, March 19th. Finally, Guggenheim dropped their target price on shares of BeiGene from $350.00 to $345.00 and set a “buy” rating for the company in a report on Tuesday, February 27th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, BeiGene has an average rating of “Moderate Buy” and an average price target of $251.70.

BeiGene Price Performance

The company’s 50-day simple moving average is $156.36 and its 200 day simple moving average is $169.45. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.09 and a current ratio of 2.32. The company has a market cap of $12.63 billion, a PE ratio of -15.71 and a beta of 0.61.

BeiGene (NASDAQ:BGNE) last released its earnings results on Monday, February 26th. The company reported ($3.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.61) by $0.08. BeiGene had a negative return on equity of 23.12% and a negative net margin of 35.86%. The firm had revenue of $634.40 million during the quarter, compared to analyst estimates of $632.52 million. During the same period last year, the business posted ($4.29) earnings per share. BeiGene’s revenue was up 66.9% compared to the same quarter last year. On average, sell-side analysts predict that BeiGene, Ltd. will post -8.87 earnings per share for the current fiscal year.

Insider Transactions at BeiGene

In related news, CEO John Oyler sold 37,668 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $164.02, for a total value of $6,178,305.36. Following the transaction, the chief executive officer now owns 12,332 shares of the company’s stock, valued at $2,022,694.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Julia Aijun Wang sold 397 shares of BeiGene stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $167.08, for a total transaction of $66,330.76. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO John Oyler sold 37,668 shares of the business’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $164.02, for a total value of $6,178,305.36. Following the completion of the sale, the chief executive officer now directly owns 12,332 shares of the company’s stock, valued at $2,022,694.64. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 64,781 shares of company stock valued at $10,222,381. 7.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. grew its position in shares of BeiGene by 26.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 244 shares of the company’s stock worth $54,000 after acquiring an additional 51 shares during the last quarter. MML Investors Services LLC raised its holdings in shares of BeiGene by 1.0% in the second quarter. MML Investors Services LLC now owns 5,245 shares of the company’s stock valued at $935,000 after buying an additional 54 shares during the last quarter. LPL Financial LLC grew its holdings in shares of BeiGene by 3.7% during the third quarter. LPL Financial LLC now owns 2,033 shares of the company’s stock worth $366,000 after buying an additional 73 shares during the last quarter. Knights of Columbus Asset Advisors LLC increased its position in BeiGene by 20.5% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 447 shares of the company’s stock valued at $80,000 after acquiring an additional 76 shares during the period. Finally, Vanguard Personalized Indexing Management LLC increased its position in BeiGene by 4.8% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 1,704 shares of the company’s stock valued at $306,000 after acquiring an additional 78 shares during the period. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.